A $1.1 million advance from Change Healthcare (“CHC”), the Company’s clearinghouse service for billing claims processing, has been repaid. CHC experienced a cybersecurity incident in 2024 and advanced ...
Earnings call Precipio reported Q3 2025 revenue of $6.8M, up 30% YoY and 20% QoQ, driven by strong performance in both Pathology Services and Products divisions. The company achieved its first ...
Precipio is a microcap specialty cancer diagnostics company offering both molecular assay kits and pathology services. Precipio currently has "going concern" language in their financial audit due to ...
Precipio, Inc., a specialty cancer diagnostics company, announced a significant agreement with its largest warrant holder, revising the exercise structure of existing warrants. Under the new terms, ...
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and ...
NEW HAVEN, Conn., July 11, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has entered into an agreement with its largest warrant holder, amending the ...
NEW HAVEN, CT / ACCESSWIRE / December 4, 2019 / Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced the resignation of Samuel Riccitelli from the board of directors, and his ...
Precipio Inc. (NASDAQ:PRPO) shares surged 140% Monday after the company successfully launched its COVID-19 rapid antibody test that tests for both IgG & IgM antibodies. Testing for antibodies will let ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results